Entrada reports Q2 net loss of $42.8M; cash $223M; multiple clinical data readouts ahead

Entrada Therapeutics, Inc.

Net loss of $42.8M in Q2 2026, roughly flat vs $43.1M in Q2 2025; collaboration revenue $0.9M.
Cash, equivalents and marketable securities $223.0M as of June 30, 2026, down from $295.7M at Dec 31, 2025; runway into Q3 2027.
ELEVATE-44-201 Cohort 1 open-label data expected by year-end 2026; Cohort 2 data in Q1 2027.
ELEVATE-45-201 Cohort 1 data expected October 2026; Cohort 2 dosing at 10 mg/kg ongoing with data in H1 2027.
Vertex to report VX-670 Phase 1/2 data in DM1 in H2 2026; Entrada advancing preclinical ocular candidate ENTR-801 for USH2A.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.